Collectively, the findings of this study were of clinical guiding significance to provide the efficacy and safety data of PD-1 inhibitor monotherapy in clinical practice for elderly patients with advanced NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.